Start Biotechnology, End Changing Regenerative Medicine

Mechanical Syringe Pump, Harvard Apparatus
Mechanical Syringe Pump, Harvard Apparatus

Ready for more regenerative medicine? We visited with the technical staff at the Harvard Apparatus Regenerative Technology group of Harvard Bioscience. Harvard Bioscience is a Holliston, MA based company that provides technology used throughout the field of regenerative medicine. The current management took the company from a $10 M to $110 M in the last 15 years, that’s more than a tenfold increase. As important as their net worth is, that isn’t what’s most important at this company. Harvard Bioscience strives to make the best possible equipment for the scientists who use their technology and reduce their research time.

Harvard Apparatus has two major technologies that are advancing science right now. The first is a clinical infusion syringe pump targeting the safety and accuracy of delivering medicine to patients in hospitals. When liquids need to be delivered at a constant and precise volume per unit of time, especially when the volumes are low, injection by hand is ineffective. Harvard Apparatus is the world leader in high precision research syringe pumps allowing doses as low as microliters per minute over an extended period of time at a programmable rate. This is combined with technology to maintain cells allowing precise delivery in cellular therapy applications such as injecting stem cells.

They also are optimizing an ex vivo isolated organ perfusion system. This system allows organs to be maintained outside the body and the effects of new drugs and treatments tested on actual organs.  

These technologies may not suggest regenerative medicine from first glance, so how did they get started with regenerative medicine? President David Green identified regenerative medicine as a possible new field to enter based on the technologies already being pioneered by the company. The Ex Vivo Profusion System as they knew it was a Bioreactor to some of their customers. The ability to keep organs alive outside of the body enabled the decellularization of organs—taking all of the donor cells out to enable stem cells from the patient to grow within the scaffolding of the organ and become a new organ. Combining collaboration with leading scientists and additional R&D on their Bioreactors, the company identified and are implementing what scientists and researchers need to advance research.

Want to know more about the bioreactors and what else Harvard Apparatus has to offer? Come check out our next few posts on their technology and how it’s being applied today. What do you think about bioreactors and their syringe pump? Let us know @TRA360!

Finding a New Future in Regenerative Medicine

Decell-Lung
Decell-Lung

After learning about the work of Dr. Geraldine Hamilton and her Wyss Institute research team at the BIO International Conference, we wanted to learn more about the strides being made in medicine now that represent the future. We stumbled across the idea of regenerative medicine and found the field incredibly interesting, and hope you do as well.

“The aim of regenerative medicine is to regenerate more fundamentally by the provision of cells, particularly stem cells that can stimulate wider regeneration.” This definition from the Future Science Group provides a scientifically accurate summary of the work in the field of regenerative medicine. But what does any of this actually mean to you and me? In more understandable words, the goal of regenerative medicine is to provide organs and tissue that can eventually be used to cure innumerable diseases.

Again I ask, what does any of this have to do with the average person? Personally, I’m not in any state of critical health, so what impact does regenerative medicine have on my life? For a holistic perspective, you have to think of your entire family and your peers. Three people come into my head immediately: one with diabetes, one with Amyotrophic Lateral Sclerosis (ALS), and one with Multiple Sclerosis (MS). I am fortunate that I do not have immediate family or friends that are waiting for a kidney, heart, or lung transplant in order to survive.

Current research conducted by scientists in regenerative medicine could someday find a cure for the diseases that impact my family, friend, and many others. Just imagine it—diabetes, Alzheimer’s, Parkinson’s, spinal cord injuries—could all be completely curable, the possibilities are endless. Even more than just the curing of diseases, millions of lives could be saved by creating these organs. Everyday 18 people die awaiting an organ transplant. That’s 6,570 individuals every year. Each of these people is someone’s son, daughter, mother, father, cousin, or other loved one. Regenerative medicine could save some of these lives.

In the next few posts we are going to profile some companies and the work they’re doing in the field of regenerative medicine. If you know someone who works in regenerative medicine, or would like to be featured yourself, contact us! 

Quanticate

Quanticate
Quanticate

Imagine being the world leader in your field with a 93% return rate of customers—amazing right? Well, you don’t have to imagine this if you’re Quanticate since it’s their reality.

Quanticate is the world’s largest Global Clinical Research Organization (CRO). They focus on data services for their customers. According to their website the company provides “clinical data management, biostatistics, clinical programming, medical writing, pharmacovigilance services and remote monitoring approaches.”  Their service saves their customers over 30% of the cost to perform the services themselves. They serve every stage of clinical trials from Phase I to Late Phase, as well as PK PD Modeling. Across the board, Quanticate provides the greatest expertise in all of their fields of service, and are compliant with all standards.

How could you go wrong with a company that is a world leader and will save you money? You can’t, and their customers have discovered this too. If you’re running a clinical trial or need to use the services of a CRO, Quanticate is worth serious consideration. Go on, become part of the 93% of customers that come back for more! Be sure to let us know what you think.

Microsoft and GE Healthcare Completes Joint Venture

The Craze for Caradigm

Two major powerhouses, Microsoft and GE Healthcare, have joined forces to “create a 50-50 joint venture that will help health systems and professionals use real-time, organization-wide intelligence to improve healthcare quality and the patient experience” (Marketwatch).

What is Caradigm?

Caradigm is the newest healthcare intelligence platform that aims to improve outcomes and economics of health and wellness. Microsoft and GE healthcare’s agreement was finalized on June 1, 2012.

What’s to come of Caradigm?

Caradigm will be lead by CEO, Michael Simpson, originally from GE Healthcare. Simpson looks forward to working with the emerging technology of Caradigm to help the continuous growth of today’s healthcare system. This new technology will enable the development of innovative healthcare solutions and software tools to better our system.

Have you heard about Caradigm? What do you think about the latest technology in the healthcare field? Comment below and let us know!